Skip to content

IBio up on advancement of IBIO-201, COVID-19 LicKM-subunit vaccine

September 9, 2020

iBio (NYSEMKT:IBIO) jumps 14% premarket on the heels of selecting IBIO-201, a proprietary lichenase carrier molecule (branded as LickM) fused to a coronavirus subunit protein, as its leading candidate for the prevention of SARS-CoV-2 infection.

The Company previously announced that preclinical immunization studies with IBIO-200 and IBIO-201, combined with select adjuvants from the Infectious Disease Research Institute (IDRI), induced anti-SARS-CoV-2 antibodies.

Additional data from cell-based pseudovirus neutralization assay testing demonstrate that IBIO-201 induced the production of more anti-spike neutralizing antibodies than IBIO-200 in immunized mice.

iBio continues to work with IDRI and the Texas A&M University System, and expects to engage additional collaborators for further characterization and testing of IBIO-201 prior to performing GLP toxicology studies.

Previously: IBio rallies on advancement of COVID-19 vaccine program (Aug. 10)

From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: